Nguyen, A., Zhou, J., Prior, T., Weidman, J., Lee, S., Minnick, P., Jonathan, D., Hodin, C., Hilder, B., Daskalakis, N., Samtani, M., Haddish-Berhane, N., Singh, I. (2025). Clinical pharmacology strategies to support dose optimization of the recommended Phase 2 dose regimen of JNJ-5322, a BCMA×GPRC5D×CD3 trispecific antibody, in Relapsed/Refractory multiple myeloma. Blood. https://doi.org/10.1182/blood-2025-4054